# A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

> **NCT03863080** · PHASE2 · COMPLETED · sponsor: **Immunovant Sciences GmbH** · enrollment: 17 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** RVT-1401
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03863080
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-21
- **Primary completion:** 2020-10-07
- **Final completion:** 2020-12-21
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03863080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03863080, "A Study of RVT-1401 in Myasthenia Gravis (MG) Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03863080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*